New breast cancer drug trial challenges standard hormone therapy
NCT ID NCT07159451
Summary
This study is testing whether a new drug called elacestrant works as well alone as it does combined with standard ovarian suppression therapy in premenopausal women with early-stage breast cancer. Researchers will give 140 participants either the single drug or the combination for four weeks before their scheduled breast surgery to see which better reduces cancer cell growth. The goal is to find simpler, effective treatment options that might avoid the side effects of ovarian suppression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gustave Roussy
RECRUITINGVillejuif, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.